Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of clinical efficacy, safety and pharmacological activity of UR-1505 in volunteers with nickel allergy
2005-005677-30Phase 2Active
- Sponsor
- Uriach
- Start
- Jan 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UR-1505 in contact hypersensitivity (3 arms), sponsored by Uriach. Primary endpoint: Physician global assessment of allergic reaction on day 4. Started Jan 2006; status: active.
02
Drugs
UR-1505
03
Conditions
contact hypersensitivity
Beyond the preview
Go deeper on 2005-005677-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005677-30.